Maryland is currently home to 2681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
NCT04117087
Recruiting
Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Colorectal Cancer, Pancreatic Cancer
Register for Updates
A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
NCT06732414
Recruiting
Background: Allergic or sinus diseases can affect the skin, sinuses, airways, and other parts of the body. Examples include pollen and environmental allergies, food allergies, asthma, and eczema. To learn more about how to prevent and treat these diseases, researchers need to study data, blood, fluid, and tissue samples from people affected by them. Objective: To collect data, blood, fluid, and tissue samples from people with allergic or sinus diseases. Eligibility: People aged 3 to 100 yea... Read More
Gender:
ALL
Ages:
Between 3 years and 100 years
Trial Updated:
01/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
Register for Updates
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543
Recruiting
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Colorectal Cancer
Register for Updates
A Study to Assess the Effects of Dexpramipexole in Participants with Eosinophilic COPD
NCT06533553
Recruiting
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
01/30/2025
Locations: Research Site US-10001-020, Baltimore, Maryland
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Multi-Center Clean Air Randomized Controlled Trial in COPD
NCT06376994
Recruiting
This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
01/30/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
PYLARIFY® PET/CT or PET/MRI in Men with Favorable Intermediate Risk (FIR) Prostate Cancer
NCT06074510
Recruiting
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer. Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cance... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Prostate Cancer
Register for Updates
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
NCT05984199
Recruiting
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: National Institutes of Health, Clinical Center, Bethesda, Maryland
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Safety and Preliminary Efficacy Trial of BNT142 in Patients with CLDN6-positive Solid Tumors
NCT05262530
Recruiting
This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Solid Tumor
Register for Updates
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS
NCT04849910
Recruiting
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/30/2025
Locations: National Institutes of Health, Clinical Center, Bethesda, Maryland
Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Register for Updates
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526
Recruiting
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Register for Updates
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Johns Hopkins Univ/Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Register for Updates
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
NCT03513614
Recruiting
RATIONALE: The use of tailored axillary dissection as a tailored procedure will avoid surgical overtreatment by selectively removing the lymph nodes that are affected by the cancer, thereby sparing many women the unnecessary complications of a radical surgery, providing a better quality of life while keeping the same efficacy. PURPOSE: The phase III trial is evaluating the optimal treatment for breast cancer patients in terms of surgery and radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Node-positive Breast Cancer
Register for Updates